CD274 and non-small cell lung carcinoma: However, only a portion of patients can benefit from NCIO, and biomarkers for selecting the most suitable populations of NSCLC are unclear, such as the suitable histology type, stage, PD-L1 expression, and peripheral blood biomarkers.